CHARLOTTE, N.C., May 1, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the first quarter 2012. Following receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in March 2012, Chelsea scheduled a meeting with the agency to discuss the additional clinical data required for approval of Northera™ (droxidopa) in the U.S. This meeting is scheduled to take place in May and, based on prior experience, Chelsea expects to receive formal meeting minutes by the end of the month at which time the Company intends to host a call to discuss the outcome of this meeting, the anticipated regulatory path for Northera and the results of the first quarter 2012.
